AIMC Topic: HIV Protease Inhibitors

Clear Filters Showing 11 to 13 of 13 articles

Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods.

European journal of medicinal chemistry Jul 6, 2015
The HIV-1 protease has proven to be a crucial component of the HIV replication machinery and a reliable target for anti-HIV drug discovery. In this study, we applied an optimized hierarchical multistage virtual screening method targeting HIV-1 protea...
Molecular Docking Simulation Support Vector Machine Dose-Response Relationship, Drug Structure-Activity Relationship Molecular Structure Drug Evaluation, Preclinical HIV Protease HIV Protease Inhibitors
View on PubMed DOI

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

HIV clinical trials Dec 1, 2018
BACKGROUND: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance.
Humans Female Reproducibility of Results Aged Adult Male Middle Aged HIV Infections Cohort Studies Pyridones Oxazines Heterocyclic Compounds, 3-Ring Piperazines Italy HIV-1 Darunavir HIV Protease Inhibitors HIV Integrase Inhibitors Salvage Therapy
View on PubMed DOI

Optimized Virtual Screening Workflow: Towards Target-Based Polynomial Scoring Functions for HIV-1 Protease.

Combinatorial chemistry & high throughput screening Jan 1, 2017
BACKGROUND: One key step in the development of inhibitors for an enzyme is the application of computational methodologies to predict protein-ligand interactions. The abundance of structural and ligand-binding information for HIV-1 protease opens up t...
Machine Learning Molecular Docking Simulation Drug Evaluation, Preclinical Ligands HIV Protease HIV Protease Inhibitors
View on PubMed DOI
Popular Topics
Recent Journals